Venetoclax and Hypomethylating Agent in Previously Untreated Higher-Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real-World Study

被引：0
|
作者：
Wang, Jing [1 ]
Fang, Zhijian [2 ]
Yang, Siyi [2 ]
Yan, Kexin [2 ]
Zhang, Jingjing [2 ]
Yu, Yanfang [2 ]
Ren, Yaoliang [2 ]
Jiang, Hao [1 ]
Jia, Jinsong [1 ]
Chen, Jianlin [2 ]
Li, Botao [2 ]
Chang, Yingjun [1 ]
Zhao, Xiaosu [1 ]
Huang, Xiaojun [1 ,3 ,4 ]
机构：
[1] Peking Univ Peoples Hosp, Peking Univ Inst Hematol, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplantat, Beijing, Peoples R China
[2] Beijing Qinghe Hosp, Dept Hematol, Beijing, Peoples R China
[3] Peking Tsinghua Ctr Life Sci, Ctr Life Sci, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Res Unit, Key Tech Diag & Treatments Hematol Malignancies, Beijing, Peoples R China
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年
关键词：
D O I：
10.1002/ajh.27532
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world
    高清妍
    China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 186
  • [2] Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
    Azizi, Armon
    Ediriwickrema, Asiri
    Dutta, Ritika
    Patel, Shyam A.
    Shomali, William
    Medeiros, Bruno
    Iberri, David
    Gotlib, Jason
    Mannis, Gabriel
    Greenberg, Peter
    Majeti, Ravindra
    Zhang, Tian
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2700 - 2707
  • [3] Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan, Amer M.
    Salimi, Tehseen
    Epstein, Robert S.
    FUTURE ONCOLOGY, 2021, 17 (36) : 5163 - 5175
  • [4] Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts
    Gangat, Naseema
    McCullough, Kristen
    Johnson, Isla
    Al-Kali, Aref
    Begna, Kebede H.
    Patnaik, Mrinal M.
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Alkhateeb, Hassan
    Mangaonkar, Abhishek
    Foran, James M.
    Badar, Talha
    Palmer, Jeanne M.
    Sproat, Lisa
    Arana Yi, Cecilia Y.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E214 - E216
  • [5] Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
    Zeidan, Amer Methqal
    Joshi, Namita
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Corman, Shelby
    Hill, Kala
    Salimi, Tehseen
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
    Bazinet, Alexandre
    Desikan, Sai Prasad
    Li, Ziyi
    Rodriguez-Sevilla, Juan Jose
    Venugopal, Sangeetha
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Kadia, Tapan M.
    Borthakur, Gautam
    Dinardo, Courtney D.
    Daver, Naval G.
    Jabbour, Elias J.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1319 - 1326
  • [7] Machine Learning Approach to Understand Real-World Treatment in Patients with Higher-Risk Myelodysplastic Syndromes
    Priya, Vandana
    Vaidya, Vivek P.
    Agrawal, Smita
    Singh, Neeraj
    Chatra, Kaveri
    Parmar, Dhaval
    Yan, Raymond
    Das, Rahul K.
    Haririfar, Mahnoush
    McMahon, Peter
    Williamson, Mellissa
    Sadek, Islam
    Hogea, Cosmina
    BLOOD, 2023, 142
  • [8] Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
    Rajakumaraswamy, Nishanthan
    Gandhi, Mitul
    Wei, Andrew H.
    Sallman, David A.
    Daver, Naval G.
    Mo, Shuyuan
    Iqbal, Shahed
    Karalliyadda, Roshan
    Chen, Manli
    Wang, Yunfei
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : 260 - 268.e2
  • [9] Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use
    Zeidan, Amer M.
    Divino, Victoria
    DeKoven, Mitch
    Shah, Drishti
    Wang, Elizabeth
    Bey, Dawn
    Salimi, Tehseen
    Epstein, Robert S.
    BLOOD, 2021, 138
  • [10] HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
    Zeidan, A. M.
    Joshi, N.
    Kale, H.
    Wang, W. -J.
    Corman, S.
    Hill, K.
    Salimi, T.
    Epstein, R.
    LEUKEMIA RESEARCH, 2021, 108 : S26 - S26
12345